QUB Prof Richard Wilson will present MErCuRIC at the EORTC-NCI-AARC Symposium

On November 16, 2018, MErCuRIC PI, Professor Richard Wilson of Queen’s University Belfast will present “A phase I dose escalation multi-centre study crizotinib (MET inhibitor) in patients with advanced solid tumours” during a “Molecular Targeted Agents” session of the EORTC-NCI-AACR Symposium. The meeting will take place on 13-16 November 2018 in The Convention Centre Dublin, in the Republic of Ireland.

Hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2018 Symposium will assemble academics, scientists and pharmaceutical industry representatives from across the globe to discuss the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology.

You can view the searchable EORTC- NCI- AACR Symposium 2018 programme here.